Asia On The Move: As China Slows, Returnees Reconsider Options
This article was originally published in PharmAsia News
The China economic slowdown appears to be starting to affect life science returnee talent, with two executives leaving their R&D and investment executive positions at top multinationals in the past few months alone. Meanwhile, the China FDA is preparing to announce a plethora of new directors and personnel changes are taking place at regional firms including ASLAN, Kyowa Hakko Kirin and Terumo.
Register for our free email digests: